Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

T1899990

Triamcinolone

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

9α-Fluoro-11β,16α,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione, 9α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, Fluoxyprednisolone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H27FO6
Número de CAS:
124-94-7
Peso molecular:
394.43
Número MDL:
MFCD00010477
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329826693
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

triamcinolone

fabricante / nombre comercial

EDQM

mp

262-263 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1

Clave InChI

GFNANZIMVAIWHM-OBYCQNJPSA-N

Información sobre el gen

human ... NR3C1(2908)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Triamcinolone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Triamcinolone is a synthetic glucocorticoid agonist; induces gene expression and apoptosis; inhibits prostaglandin synthesis; impairs tumor necrosis factor (TNF)-α-induced degradation of κB-α; potentiates the differentiation-inducing effects of bone morphogenetic proteins (BMP-2, -4, -6).

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazard
GHS08

Palabra de señalización

Warning

Frases de peligro

H351

Clasificaciones de peligro

Carc. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

A J Bircher et al.
Acta dermato-venereologica, 75(6), 490-493 (1995-11-01)
We report the case of a 27-year-old female who had an allergic contact dermatitis to topical corticosteroids belonging to the corticosteroid groups A and D. Upon oral treatment with prednisolone a disseminated exanthema began within 24 h. Patch tests revealed
Taygan Yilmaz et al.
Current pharmaceutical biotechnology, 12(3), 337-346 (2010-10-14)
Diabetic retinopathy (DR) still represents one of the leading causes of vision loss worldwide. Since this condition affects the posterior segment of the eye, topical application of ophthalmic medicines is of limited benefit, considering that they seldom reach therapeutic levels
Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema.
S D M Chen et al.
The British journal of ophthalmology, 88(6), 843-844 (2004-05-19)
Mark P Jensen et al.
The Clinical journal of pain, 31(4), 342-348 (2014-10-21)
To describe the effects of 2 pain treatments for shoulder impingement syndrome (SIS), and illustrate how investigators can use pain quality information to understand treatment response differences. This study presents pain quality data from a randomized open-label study comparing the
Peter K Kaiser
Current medical research and opinion, 21(5), 705-713 (2005-06-23)
Evidence from randomized, placebo-controlled, double-masked studies has demonstrated that verteporfin (Visudyne) therapy is effective in reducing the risk of visual acuity loss in selected groups of patients with choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Pilot studies of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico